Target Antigen Identification for Antibody–Drug Conjugate Therapy in Biliary Tract Cancer
Authors:
- Aruj DhyaniADAruj Dhyani
- Nuray TezcanNTNuray Tezcan
- Joanne F. ChouJCJoanne F. Chou
- Zeynep TarcanZTZeynep Tarcan
- Rohit ThummalapalliRTRohit Thummalapalli
- Fatema NagibFNFatema Nagib
- Orla M. FitzpatrickOFOrla M. Fitzpatrick
- Darren CowzerDCDarren Cowzer
- Danny N. KhalilDKDanny N. Khalil
- Wungki ParkWPWungki Park
- Lily V. SaadatLSLily V. Saadat
- Kevin SoaresKSKevin Soares
Open Access
- 14 October 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF11
Abstract
Purpose: Data on antibody–drug conjugates (ADC) target expression prevalence, intertumoral heterogeneity, and genomic concordance, and its effect on clinical outcomes is limited in biliary tract cancers. Experimental Design: Resected primary biliary tract cancer specimens and, when available, matched metastatic samples were assembled into tissue microarrays (TMA) and tested for CLAUDIN18.2 (CLDN18.2), c-MET, Nectin-4, TROP2, and HER2 expression by immunohistochemistry (IHC). A subset underwent targeted next-generation sequencing using MSK-IMPACT (NCT01775072). Exploratory associations of target expression with clinicopathologic parameters, genomic alterations, recurrence-free survival (RFS), and overall survival (OS) were evaluated. Results: Sixty-five patients with resected biliary tract cancer and 18 paired metastatic sites were identified—43% extrahepatic cholangiocarcinoma, 40% intrahepatic cholangiocarcinoma, and 17% gallbladder cancer. All evaluated target antigens were expressed; percent positivity and H-score ≥200 were 83% and 26% for TROP2, 75% and 26% for c-MET, 66% and 35% for Nectin-4, and 46% and 7.7% for CLDN18.2, respectively. HER2 overexpression occurred in 3.1% of tumors. Overall agreement among paired primary and metastatic samples on calling either positive or negative ranged from 43% to 75%, with the highest observed for HER2 {75%; κ = 0.29 [95% confidence interval (CI), −0.32 to 0.91]} and TROP2 (71%; κ not available) and lowest for c-MET, CLDN18.2, and Nectin-4. Frequently altered genes included TP53 (36%), SMAD4 (27%), and ELF3 (21%). We observed no significant association between target antigen expression and genomics, RFS, or OS. Conclusions: Biliary tract cancer displays frequent but heterogeneous expression of multiple ADC targets. These hypothesis-generating findings suggest inherent complexity of target protein quantification, target threshold determination, and target sampling discordance. Future studies will be required to refine our understanding of the utility of ADCs in biliary tract cancer.Keywords
Funding Information
- Memorial Sloan-Kettering Cancer Center (NCT01775072)
- National Cancer Institute (P30 CA008748)
- Cycle for Survival (CYCLE FOR SURVIVAL)
- Society of Memorial Sloan Kettering
- National Cancer Institute (R01CA309345)